Amwill Healthcare IPO Review

AMWILL HEALTHCARE is amongst India's fastest growing Dermatology companies with a keen focus on Dermatology, Trichology & Cosmetology. They focuses on modernity; the development of its products is based on "High-Tech" advanced active cosmetology and dermatology, based on natural ingredients, allopathic actives and special technique, which offer effective and visible results.

The Company is led by a group of individuals, having a strong background and extensive experience in the dermatological and pharmaceutical industry. The Promoters and Managing Directors, Tarun Gandhi and Anand Gandhi have been associated with them since the inception. They are the founding members and are actively involved in the strategic decision making for the Company, pertaining to corporate and administrative affairs, financial operations, expansion activities, business development and management of overall business. The Promoter, Tarun Gandhi heads the business development and finance and accounts divisions of the Company and the Promoter, Anand Gandhi, heads the marketing and sales, product development, dermatologist relations divisions of the Company.

The Revenues from operations for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 2,324.71 Lakh, ₹ 4,428.41 Lakh, ₹ 3,028.25 Lakh and ₹ 2,761.54 Lakh respectively. The EBITDA for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 893.04 Lakh, ₹ 1,700.27 Lakh, ₹ 441.19 Lakh, and ₹ 366.22 Lakh, respectively. The Profit after Tax for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 651.66 Lakh, ₹ 1,253.63 Lakh, ₹ 311.44 Lakh, and ₹ 257.37 Lakh respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 8.04 and post-issue EPS of ₹ 6.27 for FY24. The pre-issue P/E ratio is 13.81x, while the post-issue P/E ratio is 17.71x against the Industry P/E ratio is 36x. The company's ROCE for FY24 is 94.16%, ROE for FY24 is 73.06% and RoNW 73.06%. The Annualised EPS based on the latest financial data is ₹ 8.36 and PE ratio is 13.27x. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Amwill Healthcare showing potential listing gains of 0%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Amwill Healthcare Limited IPO for Listing gain.

Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 

About the Author
 CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms during the training period. He is good at Technical analysis and Fundamental Analysis and uses both Technical and Fundamental analysis along with five other important factors that affect the movement of the Market namely Global Market Analysis, Upcoming Event Analysis, Institutional Money Analysis, Derivative Data Analysis, and Emotions and Sentiment of Traders and Investors in his Framework called - Technical Fundamental GUIDE to find the winning Trades.